Cargando…

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran

Background: Hip, vertebral and wrist fractures are the most common consequences of osteoporosis. This study aimed at analyzing the cost-effectiveness of teriparatide (CinnoPar®), compared with alendronate and risedronate, in the treatment of women aged 60 and over with postmenopausal osteoporosis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebadi Fard Azar, Amir Ali, Rezapour, Aziz, Alipour, Vahid, Sarabi-Asiabar, Ali, Gray, Serajaddin, Mobinizadeh, Mohammadreza, Yousefvand, Mani, Arabloo, Jalal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iran University of Medical Sciences 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804430/ https://www.ncbi.nlm.nih.gov/pubmed/29445668 http://dx.doi.org/10.14196/mjiri.31.39

Ejemplares similares

Safety, effectiveness and economic aspects of maggot debridement therapy for wound healing
por: Arabloo, Jalal, et al.
Publicado: (2016)

Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate
por: Yano, Tetsuo, et al.
Publicado: (2017)

The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
por: Arabloo, Jalal, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

The productivity and its barriers in public hospitals: case study of Iran
por: Nabilou, Bahram, et al.
Publicado: (2016)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study
por: Ebadi Fardazar, Farbod, et al.
Publicado: (2019)

A systematic review of the effectiveness of catheter ablation NavX mapping system for treatment of the cardiac arrhythmia
por: Mobinizadeh, Mohammadreza, et al.
Publicado: (2015)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
por: Yang, Chengzhi, et al.
Publicado: (2020)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for the adjuvant treatment of early breast cancer: A systematic review
por: Eisavi, Mahmoud, et al.
Publicado: (2020)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis
por: Calabria, S, et al.
Publicado: (2016)

Cost-effectiveness of Colorectal Cancer Screening and Treatment Methods: Mapping of Systematic Reviews
por: Abdolahi, Hossein Mashhadi, et al.
Publicado: (2018)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Safety, effectiveness and economic evaluation of intra-operative radiation therapy: a systematic review
por: Najafipour, Farshad, et al.
Publicado: (2015)

Does leadership effectiveness correlates with leadership styles in healthcare executives of Iran University of Medical Sciences
por: Ebadifard Azar, Farbod, et al.
Publicado: (2015)

Barriers in the performance-based payment in Iran health system: Challenges and solutions
por: Hadian, Marziye, et al.
Publicado: (2021)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

Inequity in household's capacity to pay and health payments in Tehran-Iran-2013
por: Rezapour, Aziz, et al.
Publicado: (2015)

Technical efficiency and its affecting factors in Tehran’s public hospitals: DEA approach and Tobit regression
por: Sarabi Asiabar, Ali, et al.
Publicado: (2020)

Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review
por: Rezapour, Aziz, et al.
Publicado: (2022)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Telemedicine: A systematic review of economic evaluations
por: Delgoshaei, Bahram, et al.
Publicado: (2017)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
por: Tandon, Vishal R., et al.
Publicado: (2014)

Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study
por: Yang, Dazhi, et al.
Publicado: (2023)

Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial
por: Body, J.-J., et al.
Publicado: (2020)

Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
por: Panico, Annalisa, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cfo8bmark47q3ctitk2eof4esu